Dr Reddy's Laboratories (FRA:RDDA) Total Long-Term Assets: €2,523 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RDDA Dr Reddy's Laboratories Ltd FRA:RDDA
93 GF Score
Price €10.10
GF Value €11.99
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Dr Reddy's Laboratories Total Long-Term Assets?

Dr Reddy's Laboratories FRA:RDDA 93 Total Long-Term Assets is €2,523 Mil as of Jun. 2026. GuruFocus rates FRA:RDDA with a GF Score™ of 93/100 and a GF Value™ of €11.99 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Dr Reddy's Laboratories's Total Long-Term Assets for the quarter that ended in Jun. 2026 was €2,523 Mil.

Dr Reddy's Laboratories Total Long-Term Assets Related Terms

Dr Reddy's Laboratories Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Dr Reddy's Laboratories's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr Reddy's Laboratories Total Long-Term Assets Chart

Dr Reddy's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,322.51 1,335.17 1,545.52 2,596.60 2,584.90

Dr Reddy's Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,520.33 2,532.11 2,516.90 2,584.90 2,522.59
FRA:RDDA
93GF Score
Dr Reddy's Laboratories Ltd FRA:RDDA
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr Reddy's Laboratories Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €2,523 Mil mean?
Dr Reddy's Laboratories (FRA:RDDA) has a Total Long-Term Assets of €2,523 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Dr Reddy's Laboratories and its competitors.
Is Dr Reddy's Laboratories' Total Long-Term Assets too high?
Dr Reddy's Laboratories' current Total Long-Term Assets is €2,523 Mil. Overall, Dr Reddy's Laboratories has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' Total Long-Term Assets compare to ZTS?
Dr Reddy's Laboratories' Total Long-Term Assets of €2,523 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Dr Reddy's Laboratories and its competitors. Dr Reddy's Laboratories's current Total Long-Term Assets is €2,523 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (FRA:RDDA) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.99, compared to a current price of €10.10 — trading 15.8% below its estimated fair value. The current Total Long-Term Assets is €2,523 Mil. Dr Reddy's Laboratories' overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Dr Reddy's Laboratories (FRA:RDDA), the current Total Long-Term Assets is €2,523 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr Reddy's Laboratories (FRA:RDDA) Overvalued in 2026?

Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued. The current stock price of €10.10 is trading 15.8% below its estimated GF Value™ of €11.99. GuruFocus considers Dr Reddy's Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:RDDA:

  • Total Long-Term Assets: €2,523 Mil
  • GF Value™: €11.99 vs. price of €10.10 (15.8% below fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the FRA:RDDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dr Reddy's Laboratories Business Description

Address 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
93GF Score

Get the complete analysis for FRA:RDDA

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.10
Price
€11.99
GF Value